Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Biomarkers Screening by ctDNA Detection in Advanced HER2 Positive Gastric Cancer Patients Treated by Trastuzumab Plus Chemotherapy

NCT04520295 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04520295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04520295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Biomarkers Screening by ctDNA Detection in Advanced HER2 Positive Gastric Cancer Patients Treated by Trastuzumab Plus Chemotherapy
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Unknown status
Start date
May 19, 2020
Completion date
May 31, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive gastric cancer